IP Library Granted Patent US 10,888,552
Granted Patent B2
US 10,888,552 · App. 16/313,534 · Granted Jan 12, 2021

Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability

Inventor: Steven Rothman (Clayton, MO)
Assignee: Steven Rothman
A61K31/4409A61K31/14A61K31/4422A61K31/4748A61K33/00A61P15/00A61P15/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,888,552
App. No.
16/313,534
Granted
Jan 12, 2021
Kind
B2
Abstract

Compositions and methods for stimulating erogenous zones of female and male subjects are disclosed. More particularly, the present disclosure relates to compositions for topical application to the female and male genitalia that increase cell membrane excitability and to methods of using the compositions for treating sexual dysfunction and enhancing sexual arousal and facilitating orgasm.

Claims (3)

1. A method for treating sexual dysfunction in a subject in need thereof or for stimulating erogenous zones of a subject in need thereof, the method comprising: topically applying to the subject's genitalia a composition consisting essentially of: a potassium channel blocker selected from the group consisting of 4-aminopyridine; 3,4-diaminopyridine, quinidine ((S)-(6-Methoxyquinolin-4-yl)[(1S,2R,4S,5R)-5-vinylquinuclidin-2-yl]methanol), ibutilide (N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide), propafenone (1-{2-[2-Hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one), amiodarone ((2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine), vernakalant ((3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl) ethoxy]cyclohexyl}pyrrolidin-3-ol), dofetilide (N-[4-(2-{[2-(4-methane sulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide), dronedarone (N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide), and combinations thereof and a lubricant selected from the group consisting of glycerin, hydroxyethyl cellulose, xylitol, carrageenan, and combinations thereof; wherein the composition is a topical composition.

2. The method of claim 1 , wherein the potassium channel blocker is at least one of 4-aminopyridine and 3,4-diaminopyridine in an amount ranging from about 1 μM to about 10 mM.

3. The method of claim 1 , wherein the potassium channel blocker is quinidine, and is present in the composition in an amount ranging from about 10 μM to about 10 mM.

Continuity (2)
Provisional Application 62374303 · Aug 12, 2016
Related Publication 20190192493A1 · Jun 27, 2019
Cited By (4)
US 12,390,431 US 12,396,970 US 12,403,109 US 12,740,947